We are at your disposal for your questions:
Phone: +44 208 089 33 66 firstname.lastname@example.org
Dendritic Cells belong to the monocyte group and patrol the body in search of foreign bodies such as viruses, fungi or bacteria. They are derived from hematopoietic bone-marrow progenitor cells which initially transform into immature dendritic cells.
Immature dendritic cells constantly sample the surrounding environment for pathogens such as viruses and bacteria. This is done through pattern recognition receptors (PRRs) such as the toll-like receptors (TLRs).
TLRs recognize specific chemical signatures found on subsets of pathogens.
By means of our special laboratory procedures, dendritic precursor cells (which are able to grow into ‘dendritic cells’) are isolated from a patient's blood sample. During the maturation process of these precursor cells, immunologically produced tumour components are added to them, based on the patient's blood sample & the precursor cells mature into fully-formed dendritic cells, bearing the same characteristics & features of tumour cells associated with a particular receptor at their surface.
These Dendritic Cells, which are now fully developed, are then processed (without additives such as medications, etc.) to a cell suspension which is then administered to the patient subcutaneously into the region of the inguinal lymph nodes. Once inside the body of the patient, the Dendritic Cells then migrate into the lymph nodes and activate various types of executor cells. The immune system is now able to perceive & destroy degenerated & harmful cells/tumors.
Degenerative & harmful cells are generally combated by the body’s own immune system.
However, problems arise when a weakened immune system is no longer able to do so.
Successfully combatting cancer using the immune system has always been a dream of the medical community, & today this possibility has become real. When dentritic cells come into contact with a presentable antigen, they become activated & change into mature dendritic cells which then migrate to the lymph nodes.
After traveling through the blood stream to the spleen or through the lymphatic system to a lymph node they act as antigen-presenting cells:
they activate helper T-cells and killer T-cells as well as B-cells by presenting them with antigens derived from the pathogen, alongside non-antigen specific costimulatory signals.
Only professional antigen-presenting cells (macrophages, B lymphocytes, and dendritic cells) are able to activate resting helper T-cells when the matching antigen is presented. In non-lymphoid organs, macrophages and B cells can only activate memory T cells whereas dendritic cells can activate both memory and naive T cells, and are the most potent of all the antigen-presenting cells!
Dendritic Cells can survive for up to 120 days in the body, interacting with & helping other cells to produce antibodies that can combat cancer.
The advantages of dentritic cell therapy are obvious & what was unimaginable 10 years ago, is now almost standard:
Dendritic Cells can be propagated outside the human body & then used to fight cancer! Our laboratories in Germany which specialize in immunology are run by specialists with many years of experience & we are dedicated to helping you find the right solutions whether you are a doctor or a patient. Discover more about our cutting-edge treatments today!
ES- 38004 Santa Cruz de Tenerife
Calle Costa Y Grijalba 7
Phone: +44 208 089 33 66
Our treatments may also be conveniently & successfully combined with other ongoing therapies such as chemotherapy, mistletoe therapy, radiotherapy, etc.
For more information regarding our treatment options please consult your medical specialist or contact a Immumedic representative (link).